Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Net Cash Flow: 2024-2025

Historic Net Cash Flow for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $13.3 million.

  • Kura Oncology's Net Cash Flow rose 210.43% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.8 million, marking a year-over-year change of. This contributed to the annual value of $187.1 million for FY2024, which is 1392.07% up from last year.
  • Kura Oncology's Net Cash Flow amounted to $13.3 million in Q3 2025, which was down 56.52% from $30.7 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Net Cash Flow registered a high of $175.0 million during Q4 2024, and its lowest value of -$173.2 million during Q1 2025.
  • In the last 2 years, Kura Oncology's Net Cash Flow had a median value of $4.3 million in 2024 and averaged $8.3 million.
  • Over the last 5 years, Kura Oncology's Net Cash Flow had its largest YoY gain of 734.35% in 2025, and its largest YoY loss of 4,235.46% in 2025.
  • Quarterly analysis of 2 years shows Kura Oncology's Net Cash Flow stood at $175.0 million in 2024, then soared by 210.43% to $13.3 million in 2025.
  • Its Net Cash Flow stands at $13.3 million for Q3 2025, versus $30.7 million for Q2 2025 and -$173.2 million for Q1 2025.